After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
We are very excited to launch our new website! Please take a few moments to click around and explore...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...